Literature DB >> 11695714

Effect of lamotrigine on the pharmacokinetics of carbamazepine and its active metabolite in dogs.

K M Matar1, P J Nicholls, S A Bawazir, K I Al-Khamis, M I Al-Hassan.   

Abstract

The effect of lamotrigine (LTG) on the pharmacokinetics of carbamazepine (CBZ) and its active metabolite; carbamazepine-epoxine (CBZ-E), was investigated in dogs. Five male dogs received CBZ (2 x 200 mg tab, p.o.) daily for a period of 1 week. After the end of this period, blood samples were collected serially for up to 24 hrs. After a wash-out period of I week, LTG (100 mg tab, p.o.) was coadministered with the CBZ dose (2 x 200 mg tab, p.o.) for 7 days. Blood samples were again serially collected and plasma levels of CBZ and CBZ-E were analysed by high performance liquid chromatography (HPLC). Concurrent administration of LTG with CBZ did not have any significant effect on the pharmacokinetic parameters of CBZ. There was also no significant difference between the plasma concentration ratio (CBZ-E to CBZ) vs time profiles in the two schedules of drug administration signifying the absence of pharmacokinetic interaction between LTG and CBZ or its active metabolite in this animal model.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11695714     DOI: 10.1007/BF03190390

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  13 in total

Review 1.  Clinically significant pharmacokinetic drug interactions with carbamazepine. An update.

Authors:  E Spina; F Pisani; E Perucca
Journal:  Clin Pharmacokinet       Date:  1996-09       Impact factor: 6.447

2.  Carbamazepine toxicity with lamotrigine: pharmacokinetic or pharmacodynamic interaction?

Authors:  F M Besag; D J Berry; F Pool; J E Newbery; B Subel
Journal:  Epilepsia       Date:  1998-02       Impact factor: 5.864

Review 3.  Newer antiepileptic drugs: gabapentin, lamotrigine, felbamate, topiramate and fosphenytoin.

Authors:  W J Curry; D L Kulling
Journal:  Am Fam Physician       Date:  1998-02-01       Impact factor: 3.292

4.  Lamotrigine-induced carbamazepine toxicity: an interaction with carbamazepine-10,11-epoxide.

Authors:  T Warner; P N Patsalos; M Prevett; A A Elyas; J S Duncan
Journal:  Epilepsy Res       Date:  1992-04       Impact factor: 3.045

5.  No increase in carbamazepine-10,11-epoxide during addition of lamotrigine treatment in children.

Authors:  A S Eriksson; L O Boreus
Journal:  Ther Drug Monit       Date:  1997-10       Impact factor: 3.681

6.  Effect of lamotrigine on carbamazepine epoxide/carbamazepine serum concentration ratios in adult patients with epilepsy.

Authors:  B E Gidal; P Rutecki; R Shaw; M M Maly; D M Collins; M E Pitterle
Journal:  Epilepsy Res       Date:  1997-10       Impact factor: 3.045

7.  Liquid chromatographic determination of six antiepileptic drugs and two metabolites in microsamples of human plasma.

Authors:  K M Matar; P J Nicholls; A Tekle; S A Bawazir; M I Al-Hassan
Journal:  Ther Drug Monit       Date:  1999-10       Impact factor: 3.681

Review 8.  Clinical pharmacokinetics and pharmacological effects of carbamazepine and carbamazepine-10,11-epoxide. An update.

Authors:  L Bertilsson; T Tomson
Journal:  Clin Pharmacokinet       Date:  1986 May-Jun       Impact factor: 6.447

Review 9.  Optimisation of antiepileptic drug therapy. The importance of serum drug concentration monitoring.

Authors:  E Yukawa
Journal:  Clin Pharmacokinet       Date:  1996-08       Impact factor: 6.447

10.  Single dose pharmacokinetics of carbamazepine-10,11-epoxide in patients on lamotrigine monotherapy.

Authors:  F Pisani; B Xiao; A Fazio; E Spina; E Perucca; T Tomson
Journal:  Epilepsy Res       Date:  1994-12       Impact factor: 3.045

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.